An Opinion Too Far—The Campaign Against the Surviving Sepsis Campaign

This publication has 14 references indexed in Scilit:

• Surviving Sepsis — Practice Guidelines, Marketing Campaigns, and Eli Lilly
  New England Journal of Medicine, 2006
• Efficacy and Safety of Drotrecogin Alfa (Activated) for the Therapy of Surgical Patients with Severe Sepsis
  Surgical Infections, 2006
• Temporary Insanity?
  Surgical Infections, 2005
• Defining the standard of care in randomized controlled trials of titrated therapies
  Current Opinion in Critical Care, 2004
• Substantiating the concerns about recombinant human activated protein C use in sepsis*
  Critical Care Medicine, 2004
• Recombinant Human Activated Protein C in Sepsis: Assessing Its Clinical Use
  The Lancet Healthy Longevity, 2004
• Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness
  Current Opinion in Infectious Diseases, 2004
• Surviving Sepsis
  Surgical Infections, 2004
• Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
  Critical Care Medicine, 2004
• Risks and Benefits of Activated Protein C Treatment for Severe Sepsis
  New England Journal of Medicine, 2002